How to Cite
Abstract
Introduction. Signet-ring cell carcinoma (SRCC) is a rare tumor and is associated with poor prognosis and low sensitivity to non-surgical treatment methods.
Aim. The purpose of our study was to investigate whether adjuvant chemotherapy (ACT) could enhance the prognosis, despite the conflicting data on its efficacy.
Materials and methods. We conducted a retrospective analysis of medical records for patients diagnosed with SRCC who received treatment at the N.N. Blokhin National Medical Research Center of Oncology between 2000 and 2020. Inclusion criteria were histologically verified primary SRCC, stage II-III disease, initial surgical treatment, and tumor localization in the colon. The main evaluated parameters were overall survival (OS) and relapse-free survival (RFS).
Results. We studied two patient groups: 25 (47.2 %) received ACT (XELOX, FOLFOX) and 26 (49 %) did not receive ACT. The median follow-up time was 100.0 months. The 5-year OS was 24.6 % in the ACT group and 42.0 % in the non-ACT group (р = 0.072), 5-year RFS was 24.9 % and 35.5 %, respectively (р = 0.161).
Conclusion. In our study, ACT did not impact the prognosis. However, additional research is needed to confirm the obtained results.
References
International Agency for Research on Cancer. World Health Organization. Cancer Today [Internet]. Available from: https://gco.iarc.fr/today/online-analysis-multi-bars (Accessed: March 3, 2023).
Weizt J, Koch M, Debus J, et al. Colorectal cancer. Lancet. 2005;365(9454):153-165. https://doi.org/10.1016/S0140-6736(05)17706-X.
Vallam KC, Desouza A, Bal M, et al. Adenocarcinoma of the rectum-a composite of three different subtypes with varying outcomes? Clin Colorectal Cancer. 2016;15(2):e47-52. https://doi.org/10.1016/j.clcc.2015.12.004.
Arifi S, Elmesbahi O, Amarti Riffi A. Primary signet ring cell carcinoma of the colon and rectum. Bull. Cancer. 2015;102:880-8. https://doi.org/10.1016/j.bulcan.2015.07.005.
Lee WS, Chun HK, Lee WY, et al. Treatment outcomes in patients with signet ring cell carcinoma of the colorectum. Am J Surg. 2007;194(3):294-8. https://doi.org/10.1016/j.amjsurg.2006.12.041.
Zhao Z, Yan N, Pan S, et al. The value of adjuvant chemotherapy in stage II/III colorectal signet ring cell carcinoma. Sci Rep. 2020;10(1):14126. https://doi.org/10.1038/s41598-020-70985-0.
Дудаев З.А., Худоеров Д.Х., Мамедли З.З., и др. Непосредственные и отдаленные результаты лечения пациентов с раком среднеи нижнеампулярного отделов прямой кишки с клиническим и патоморфологическим полным ответом после комбинированной терапии. Тазовая хирургия и онкология. 2022;12(1):41-48 [Dudayev ZA, Khudoyerov DKh, Mammadli ZZ. Immediate and long-term results of treatment of patients with cancer of the middle and lower ampulla of the rectum with clinical and pathomorphological complete response after combination therapy. Pelvic Surgery and Oncology. 2022;12(1):41-48 (In Russ.)].
Gill S, Loprinzi CL, Sargent DJ, et al. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol. 2004;22(10):1797-806. https://doi.org/10.1200/JCO.2004.09.059.
Hugen N, Verhoeven RH, Lemmens VE, et al. Colorectal signet-ring cell carcinoma: benefit from adjuvant chemotherapy but a poor prognostic factor. Int J Cancer. 2015;136(2):333-9. https://doi.org/10.1002/ijc.28981.
Shi T, Huang M, Han D, et al. Chemotherapy is associated with increased survival from colorectal signet ring cell carcinoma with distant metastasis: a surveillance, epidemiology, and end results database analysis. Cancer Med. 2019;8(4):1930-40. https://doi.org/10.1002/cam4.2054.
Argilés G, Tabernero J, Labianca R, et al. Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(10):1291-305. https://doi.org/10.1016/j.annonc.2020.06.022.
Федянин М.Ю., Гладков О.А., Гордеев С.С., и др. Практические рекомендации по лекарственному лечению рака ободочной кишки, ректосигмоидного соединения и прямой кишки. Злокачественные опухоли: Практические рекомендации RUSSCO #3s2. 2022;12:401-454 [Fedyanin MYu, Gladkov OA, Gordeev SS. Practical guidelines for the drug treatment of colorectal, rectosigmoid junction and rectal cancers. Malignant Tumors: Practice Guidelines RUSSCO #3s2. 2022;12:401-454 (In Russ.)].
Cabibi D, Calascibetta A, Campione M, et al. Clinical relevance of thymidylate synthase expression in the signet ring cell histotype component of colorectal carcinoma. Eur J Cancer. 2004;40(18):2845-50. https://doi.org/10.1016/j.ejca.2004.07.034.
Cabibi D, Calascibetta A, Aragona F, et al. Differing expression of metalloprotease and of adhesion molecules in signet-ring cell and intestinal colorectal carcinoma. Anticancer Res. 2009;29(11):4417-22.
Ling CR, Wang R, Wang MJ, et al. Prognosis and value of preoperative radiotherapy in locally advanced rectal signet-ring cell carcinoma. Sci Rep. 2017;7:45334. https://doi.org/10.1038/srep45334.
Börger ME, Gosens MJ, Jeuken JW, et al. Signet ring cell differentiation in mucinous colorectal carcinoma. J Pathol. 2007;212(3):278-86. https://doi.org/10.1002/path.2181.
Гордеев С.С., Загидуллина А.А., Нагуслаева А.А. и др. Эффективность предоперационной лучевой терапии у пациентов с перстневидноклеточным раком прямой кишки: ретроспективное исследование случай-контроль. Злокачественные опухоли 2022;12(3):5-10 [Gordeev m SS, Zagidullina AA, Naguslaeva АА, et al. The efficacy of neoadjuvant radiotherapy in patients with signet ring cell carcinoma of the rectum: a retrospective case control study. Malignant tumours. 2022;12(3):5-10 (In Russ.)]. https://doi.org/10.18027/2224-5057-2022-12-3-5-10.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
© АННМО «Вопросы онкологии», Copyright (c) 2023